Creative Medical Technology Holdings Inc Ordinary Shares CELZ 深 沪
已收盘 12-19 16:00:00 美东时间
2.11
-0.110
-4.95%
华盛通- 最 高2.2483
- 今 开2.17
- 成交量 4.87万股
- 最 低 2.11
- 昨 收 2.22
- 总市值 544.49万
- 52周最高 6.90
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.69
- 委 比 76.86%
- 总股本 258.05万
- 历史最高 51.45
- 量 比 0.79
- 振 幅 6.23%
- 历史最低 1.69
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Creative Medical Technology Completes Patient Enrollment In FDA-Cleared ADAPT Clinical Trial For CELZ-201
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its
12-17 22:16
Creative Medical Technology Holdings Says WHO Assigns "Olastrocel" As International Non-Proprietary Name For Lead Cell Therapy CELZ-201
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced
12-02 22:19
Creative Medical Technology Approves Executive Bonuses
The latest update is out from Creative Medical Technology Holdings ( ($CELZ) )....
11-12 19:47
快讯 | Creative Medical Technology Holdings 宣布达成认股权证行使协议，获得 420 万美元的总收益
Creative Medical Technology Holdings Announces Agreements for Exercise of Warra...
10-29 21:00
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. (CELZ) has entered into agreements with certain warrant holders to exercise outstanding warrants for up to 1,116,136 shares at $3.75 per share, generating approximately $4.2 million in gross proceeds. The company will issue new warrants for up to 2,790,340 shares, exercisable at $3.75 per share, subject to potential price reduction. The transaction is expected to close on October 29, 2025, with proceeds ...
10-29 13:00
Creative Medical Technology Holdings Issues Letter to Shareholders
Creative Medical Technology Holdings, Inc. reported significant progress in 2025, advancing its regenerative immunotherapy platforms: AlloStem, ImmCelz, and iPScelz. The company is conducting Phase II trials targeting chronic lower back pain and Type 1 Diabetes, with expected 2026 results. Enhanced by recent patents and AI integration, Creative Medical aims to revolutionize regenerative medicine while maintaining financial discipline and strategi...
10-27 12:15
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
Creative Medical Technology Holdings celebrated the 2025 Nobel Prize in Physiology or Medicine awarded to researchers for foundational work on regulatory T cells (Tregs), which aligns with their ImmCelz™ platform. The Company recently received two new U.S. Patents: one for treating Type 1 Diabetes and another for heart failure, both leveraging supercharged Tregs. With a focus on regenerative immunotherapy, Creative Medical aims to expand its IP p...
10-07 13:15
Creative Medical Technology shares are trading higher after the company received FDA fast track designation for CELZ-201-DDT in degenerative disc disease.
Creative Medical Technology shares are trading higher after the company receive...
08-13 21:03
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. announces that the FDA has granted Fast Track designation to its CELZ-201-DDT therapy for treating degenerative disc disease (DDD), a leading cause of chronic lower back pain. The Fast Track status facilitates accelerated review and development, potentially speeding market access. CELZ-201-DDT, part of the company's AlloStem® platform, is a minimally invasive, allogeneic perinatal cell therapy showing pr...
08-13 13:01
Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
Creative Medical Technology Holdings, Inc. has received a Notice of Allowance from the USPTO for a patent titled “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.” Once granted, the patent will remain in effect until at least 2040. The patent enables a cell-based immunotherapy approach using the ImmCelz product, which involves supercharged T regulatory cells derived from the patient’s own immune ...
07-17 13:15
